Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 130

1.

Endometrial squamous metaplasia. An unusual response to progestin therapy of hyperplasia.

Miranda MC, Mazur MT.

Arch Pathol Lab Med. 1995 May;119(5):458-60.

PMID:
7748076
[PubMed - indexed for MEDLINE]
2.

Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins.

Wheeler DT, Bristow RE, Kurman RJ.

Am J Surg Pathol. 2007 Jul;31(7):988-98.

PMID:
17592264
[PubMed - indexed for MEDLINE]
3.

Progestin therapy of complex endometrial hyperplasia with and without atypia.

Reed SD, Voigt LF, Newton KM, Garcia RH, Allison HK, Epplein M, Jordan D, Swisher E, Weiss NS.

Obstet Gynecol. 2009 Mar;113(3):655-62. doi: 10.1097/AOG.0b013e318198a10a.

PMID:
19300331
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Apoptosis may be an early event of progestin therapy for endometrial hyperplasia.

Amezcua CA, Lu JJ, Felix JC, Stanczyk FZ, Zheng W.

Gynecol Oncol. 2000 Nov;79(2):169-76.

PMID:
11063639
[PubMed - indexed for MEDLINE]
5.

Mechanisms involved in the evolution of progestin resistance in human endometrial hyperplasia--precursor of endometrial cancer.

Wang S, Pudney J, Song J, Mor G, Schwartz PE, Zheng W.

Gynecol Oncol. 2003 Feb;88(2):108-17.

PMID:
12586588
[PubMed - indexed for MEDLINE]
6.

[Outcome analysis of conservative treatment of well-differentiated endometrial adenocarcinoma and severe atypical hyperplasia in young women].

Yu M, Shen K, Yang JX, Huang HF, Wu M, Pan LY, Lang JH, Lian LJ.

Zhonghua Fu Chan Ke Za Zhi. 2006 Apr;41(4):242-5. Chinese.

PMID:
16759458
[PubMed - indexed for MEDLINE]
8.

Increased natural killer cells and decreased regulatory T cells are seen in complex atypical endometrial hyperplasia and well-differentiated carcinoma treated with progestins.

Witkiewicz AK, McConnell T, Potoczek M, Emmons RV, Kurman RJ.

Hum Pathol. 2010 Jan;41(1):26-32. doi: 10.1016/j.humpath.2009.06.012. Epub 2009 Sep 4.

PMID:
19733383
[PubMed - indexed for MEDLINE]
9.

Clinical and pathological responses of progestin therapy for non-atypical endometrial hyperplasia: a prospective study.

Rattanachaiyanont M, Angsuwathana S, Techatrisak K, Tanmahasamut P, Indhavivadhana S, Leerasiri P.

J Obstet Gynaecol Res. 2005 Apr;31(2):98-106.

PMID:
15771634
[PubMed - indexed for MEDLINE]
10.

[Endometrial atypical complex hyperplasia with extensive squamous metaplasia: two cases].

Hannachi Sassi S, Dhouib R, Abbes I, Braham E, Mrad K, Driss M, Ben Hamida N, Ben Romdhane K.

Ann Pathol. 2008 Jun;28(3):233-6. doi: 10.1016/j.annpat.2008.06.005. Epub 2008 Jul 25. French.

PMID:
18706369
[PubMed - indexed for MEDLINE]
11.

Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40.

Randall TC, Kurman RJ.

Obstet Gynecol. 1997 Sep;90(3):434-40.

PMID:
9277658
[PubMed - indexed for MEDLINE]
12.

Down-regulation of bcl-2 is a potential marker of the efficacy of progestin therapy in the treatment of endometrial hyperplasia.

Amezcua CA, Zheng W, Muderspach LI, Felix JC.

Gynecol Oncol. 1999 Apr;73(1):126-36.

PMID:
10094893
[PubMed - indexed for MEDLINE]
13.

Development of metastatic endometrial endometrioid adenocarcinoma while on progestin therapy for endometrial hyperplasia.

Rubatt JM, Slomovitz BM, Burke TW, Broaddus RR.

Gynecol Oncol. 2005 Nov;99(2):472-6. Epub 2005 Aug 15.

PMID:
16099019
[PubMed - indexed for MEDLINE]
14.

Involution of PTEN-null endometrial glands with progestin therapy.

Zheng W, Baker HE, Mutter GL.

Gynecol Oncol. 2004 Mar;92(3):1008-13.

PMID:
14984979
[PubMed - indexed for MEDLINE]
15.

Clinical significance of a cytologic diagnosis of atypical glandular cells, favor endometrial origin, in Pap smears.

Saad RS, Takei H, Liu YL, Silverman JE, Lipscomb JT, Ruiz B.

Acta Cytol. 2006 Jan-Feb;50(1):48-54.

PMID:
16514840
[PubMed - indexed for MEDLINE]
16.

Reverse of progestin-resistant atypical endometrial hyperplasia by metformin and oral contraceptives.

Shen ZQ, Zhu HT, Lin JF.

Obstet Gynecol. 2008 Aug;112(2 Pt 2):465-7. doi: 10.1097/AOG.0b013e3181719b92.

PMID:
18669766
[PubMed - indexed for MEDLINE]
17.

Endometrial hyperplasia with secretory changes.

Tresserra F, Lopez-Yarto M, Grases PJ, Ubeda A, Pascual MA, Labastida R.

Gynecol Oncol. 2003 Mar;88(3):386-93.

PMID:
12648591
[PubMed - indexed for MEDLINE]
18.

Aberrant survivin expression in endometrial hyperplasia: another mechanism of progestin resistance.

Chen X, Zhang Z, Feng Y, Fadare O, Wang J, Ai Z, Jin H, Gu C, Zheng W.

Mod Pathol. 2009 May;22(5):699-708. doi: 10.1038/modpathol.2009.25. Epub 2009 Mar 13.

PMID:
19287462
[PubMed - indexed for MEDLINE]
Free Article
19.

Complex hyperplasia with and without atypia: clinical outcomes and implications of progestin therapy.

Reed SD, Newton KM, Garcia RL, Allison KH, Voigt LF, Jordan CD, Epplein M, Swisher E, Upson K, Ehrlich KJ, Weiss NS.

Obstet Gynecol. 2010 Aug;116(2 Pt 1):365-73. doi: 10.1097/AOG.0b013e3181e93330.

PMID:
20664397
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Biomarkers of progestin therapy resistance and endometrial hyperplasia progression.

Upson K, Allison KH, Reed SD, Jordan CD, Newton KM, Swisher EM, Doherty JA, Garcia RL.

Am J Obstet Gynecol. 2012 Jul;207(1):36.e1-8. doi: 10.1016/j.ajog.2012.05.012. Epub 2012 May 16.

PMID:
22727345
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk